Melanoma by the State: North Dakota
…the community. They selected melanoma in 2018. Work began immediately. Right away, they felt that a patient story would impact…
Melanoma by the State: North Dakota
…the community. They selected melanoma in 2018. Work began immediately. Right away, they felt that a patient story would impact…
,
Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma
Source: University of Pittsburgh (September 20, 2021) An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage…
,
,
Walking to Conquer Melanoma: Mike’s Miracle Workers
By Mara Klecker Even when the pandemic forced the KDB Melanoma 5k Walk/Run to go virtual in 2020, Mike’s Miracle…
,
,
Shannon Eberly, Stage IV Melanoma Survivor- Sharing is Everything
By Mara Klecker Shannon Eberly is fair-skinned and freckled, but she never had a mole on her skin that looked…
,
Steve Banks, Stage III Survivor, Doesn’t Let Melanoma Define His Life
…doctors removed his primary site of melanoma about a decade ago. “I’m an upfront and honest person,” Steve said. “But…
,
Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors
…melanoma,” said Israel Lowy, M.D., Ph.D., Senior Vice President, Translational and Clinical Sciences, Oncology at Regeneron. “Combining LAG-3 and PD-1…
,
Diagnosed with Melanoma as a Teenager Changed My Life’s Course
…than 1% of all new cases of melanoma. Madison’s doctor said she was the youngest melanoma patient he’d ever treated.…
,
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
,
,
Reva Foy: Living Her Best Life, Despite Melanoma
…healing, she saw a podiatrist. “He took one look and said, ‘I think it’s melanoma,’” Reva remembers about that day…
,
Replimune Announces BLA Acceptance and Priority Review for RP1 for the Treatment in Advanced Melanoma
…patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for anti-CTLA-4 treatment. For more…
,
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026